Exenatide
First-in-class GLP-1 mimetic derived from Gila monster venom; sold as Byetta/Bydureon.
Appetite or glycemic effects within the first days; full effect accrues over weeks to months alongside titration.
Store the lyophilized powder refrigerated (2 to 8 C), or frozen for long-term storage, protected from light. After reconstitution with bacteriostatic water, keep refrigerated and use within about 4 weeks.
Clinical Evidence
What the literature says
Scientific Overview
Exenatide is a 39-aa synthetic version of exendin-4 from Heloderma suspectum (Gila monster) saliva. It was the first GLP-1 receptor agonist FDA-approved (Byetta, 2005, Amylin/Lilly), with a microsphere weekly formulation Bydureon following in 2012. Largely displaced by liraglutide, semaglutide, and tirzepatide.
Citations (4)
- Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical resultsPubMed
- Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitusPubMed
- Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1PubMed
- Exenatide once weekly for the treatment of type 2 diabetesPubMed
Research Guide
How users approach this compound
The following reflects patterns observed in research literature and community protocols. This is not medical advice and does not constitute a clinical recommendation.
Research Protocols
Common DosagesT2DM
“Within 60 min before meals (Byetta)”
Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.
Key Research Benefits
- HbA1c reduction
- Modest weight loss
- Long-acting weekly form available
Potential Side Effects
Labs to monitor
Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.
- HbA1c: Primary glycemic efficacy marker for incretin therapy.
- Fasting glucose: Tracks glycemic response and hypoglycemia risk in combination therapy.
- Lipid panel / ApoB: Incretin therapy commonly improves atherogenic lipids alongside weight loss.
Dose Calculator
Peptide Reconstitution Calculator
Total amount of peptide in the vial.
Volume of water used to mix.
Draw to this mark
or 0.00 mL on a U-100 syringe
Exenatide by goal
Read Exenatide's profile filtered through specific research goals.
Related Tools
Not medical advice
Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.